
1. plos pathog. 2016 apr 15;12(4):e1005545. doi: 10.1371/journal.ppat.1005545.
ecollection 2016 apr.

a subset latency-reversing agents expose hiv-infected resting cd4+ t-cells 
recognition cytotoxic t-lymphocytes.

jones rb(1)(2)(3), mueller s(2), o'connor r(1), rimpel k(1), sloan dd(4), karel
d(1), wong hc(5), jeng ek(5), thomas as(1)(3), whitney jb(1)(6), lim sy(6),
kovacs c(7)(8), benko e(7), karandish s(3), huang sh(3), buzon mj(1), lichterfeld
m(1), irrinki a(4), murry jp(4), tsai a(4), yu h(4), geleziunas r(4), trocha
a(1), ostrowski ma(8)(9), irvine dj(2)(10)(11), walker bd(1)(10).

author information: 
(1)the ragon institute massachusetts general hospital, massachusetts institute
of technology, harvard university, cambridge, massachusetts, united states of
america.
(2)koch institute integrative cancer research, mit, cambridge, massachusetts,
united states america.
(3)department microbiology immunology tropical medicine, george
washington university, washington, d.c., united states america.
(4)gilead sciences, foster city, california, united states america.
(5)altor bioscience corporation, miramar, florida, united states america.
(6)center virology vaccine research, beth israel deaconess medical
center, harvard medical school, boston, massachusetts, united states america.
(7)the maple leaf medical clinic, toronto, ontario, canada.
(8)department medicine, university toronto, toronto, ontario, canada.
(9)li ka shing medical institute, st. michael's hospital, toronto, ontario,
canad.
(10)howard hughes medical institute, chevy chase, maryland, united states of
america.
(11)department biological engineering, mit, cambridge, massachusetts, united
states america.

resting cd4+ t-cells harboring inducible hiv proviruses critical reservoir 
in antiretroviral therapy (art)-treated subjects. cells express little to
no viral protein, thus neither die viral cytopathic effects, are
efficiently cleared immune effectors. elimination reservoir is
theoretically possible combining latency-reversing agents (lras) immune
effectors, cd8+ t-cells. however, relative efficacy different lras
in sensitizing latently-infected cells recognition hiv-specific cd8+
t-cells determined. address this, developed assay that
utilizes hiv-specific cd8+ t-cell clones biosensors hiv antigen
expression. testing multiple cd8+ t-cell clones primary cell model
of hiv latency, identified several single agents primed latently-infected
cells cd8+ t-cell recognition, including il-2, il-15, two il-15 superagonists
(il-15sa alt-803), prostratin, tlr-2 ligand pam3csk4. contrast, we
did observe cd8+ t-cell recognition target cells following treatment 
histone deacetylase inhibitors hexamethylene bisacetamide (hmba). in
further experiments demonstrate clinically achievable concentration 
the il-15 superagonist 'alt-803', agent presently clinical trials solid
and hematological tumors, primes natural ex vivo reservoir cd8+ t-cell
recognition. thus, results establish novel experimental approach for
comparative evaluation lras, highlight alt-803 lra the
potential synergize cd8+ t-cells hiv eradication strategies.

doi: 10.1371/journal.ppat.1005545 
pmcid: pmc4833318
pmid: 27082643  [indexed medline]

